Notebook

Table of Contents Priviledged Information The Appeal of Creation Hungry for Life Petit Moues Model Women in Trials Keep on Smiling New-Look FDA? The United States Securities and Exchange Commission (SEC) filed an insider trading complaint against a Columbia University professor on September 28. The complaint names Dale J. Lange, a professor of neurology at Columbia's College of Physicians and Surgeons, and six others for trading in Cephalon Inc. securities prior to the West Chester, Pa.-base

The Scientist Staff
Oct 26, 1997

Table of Contents
The United States Securities and Exchange Commission (SEC) filed an insider trading complaint against a Columbia University professor on September 28. The complaint names Dale J. Lange, a professor of neurology at Columbia's College of Physicians and Surgeons, and six others for trading in Cephalon Inc. securities prior to the West Chester, Pa.-based company's public announcement of favorable research results. Lange served as an investigator for Cephalon's clinical trials of Myotrophin, a drug developed to treat Lou Gehrig's disease. SEC alleges that Lange made a profit of $26,496 from shares of Cephalon purchased prior to the June 12, 1995, public announcement that Myotrophin slowed the progression of the disease. Cephalon stock, which is traded on NASDAQ, climbed more than seven points to close at $18.375 on the...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?